Category Archives: Clinical Trials & Medical Discoveries

Cryoport Delivers Biological Samples for International Space Station; Rocket Launched Today Arrives at International Space Station on Monday

Posted on in Clinical Trials & Medical Discoveries, Finance News, Surveys, Polls and Research | 0 comments

IRVINE, Calif., June 29, 2018 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (“Company”), the world’s leading temperature controlled logistics company dedicated to the life sciences industry, announced that biological samples transported by Cryoport were launched today at 5:42 am EDT on SpaceX’s Falcon 9 rocket which took off from Cape Canaveral in Florida to the International…

El ultrasonido centrado de INSIGHTEC consigue una dirección positiva NICE para el tratamiento del tremor esencial

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

LONDRES, June 25, 2018 /PRNewswire/ — La talamotomía unilateral de ultrasonidos centrados guiada MRI para el tratamiento del tremor esencial resistente al tratamiento es reconocida por el National Institute for Health and Care Excellence

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Canc

Posted on in Clinical Trials & Medical Discoveries, Conference Call Announcements, Finance News, Trade Show News | 0 comments

BOULDER, Colo., June 23, 2018 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal…

La tecnologia a ultrasuoni focalizzati di INSIGHTEC ottiene un giudizio positivo NICE per la cura del tremore essenziale

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

LONDRA, June 21, 2018 /PRNewswire/ — La talamotomia unilaterale a ultrasuoni focalizzati a guida MRI per il tremore essenziale refrattario alle cure è stata premiata dal National Institute for Health and Care Excellence

Carmentix announces collaboration for clinical Preterm Birth study

Posted on in Clinical Trials & Medical Discoveries, Contracts, Finance News | 0 comments

SINGAPORE, June 19, 2018 /PRNewswire/ — Carmentix Pte. Ltd. is proud to announce a research collaboration with The University of Melbourne (UoM), The Chinese University Hong Kong (CUHK) and The Henan Province People’s Hospital for a clinical Preterm Birth study to validate Carmentix’s prognostic tool for predicting premature birth.

AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)

Posted on in Clinical Trials & Medical Discoveries, Finance News, Trade Show News | 0 comments

NORTH CHICAGO, Ill., June 12, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe rheumatoid arthritis.1,2,3 Improvements…

Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

Posted on in Clinical Trials & Medical Discoveries, Finance News, Trade Show News | 0 comments

NORTH CHICAGO, Ill., June 3, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA® (venetoclax) in previously-untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. Early results of the combination oral regimen suggest promising activity in treatment-naïve…

Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 Plus FOLFOX in Hepatocellular Carcinoma

Posted on in Clinical Trials & Medical Discoveries, Finance News, Trade Show News | 0 comments

SAN DIEGO, June 3, 2018 /PRNewswire/ — Polaris Group announced results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with FOLFOX demonstrated promising efficacy for heavily pre-treated hepatocellular carcinoma (HCC) patients.  The results were presented by Dr. James Harding from Memorial Sloan Kettering Cancer Center at the American…

Getinge divulga resultados do estudo-piloto SEMPER FI sobre a bomba de balão intra-aórtico que mostram a tendência numérica de redução de mortalidade em pacientes com infarto do miocárdio extensivo e isquemia persistente

Posted on in Clinical Trials & Medical Discoveries, Finance News, Trade Show News | 0 comments

WAYNE, Nova Jersey, 27 de maio de 2018 /PRNewswire/ — A Getinge, importante provedora global de tecnologia médica inovadora, divulgou hoje os resultados do estudo-piloto sobre a “Melhoria da sobrevivência em casos de infarto do miocárdio extensivo com isquemia persistente após implantação de IABP (SEMPER FI). O estudo avaliou o uso da bomba de balão…

ATL1103 Phase II trial results published in the European Journal of Endocrinology

Posted on in Clinical Trials & Medical Discoveries, Finance News | 0 comments

MELBOURNE, Australia, May 24, 2018 /PRNewswire/ — Antisense Therapeutics (the “Company” or “ANP”) is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-reviewed medical journal, the European Journal of Endocrinology.